Immunomedics, Inc.
http://www.immunomedics.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Immunomedics, Inc.
Gilead Keeps Focus On HIV, Long-Acting Drugs And Growth Through Oncology
Even with top-seller Biktarvy and its preventive therapy, Descovy, protected beyond this decade from generics, Gilead is investing aggressively in long-acting HIV candidates and its oncology pipeline.
US FDA Has History Of Pushing Sponsors On Confirmatory Trials … Sometimes
Even before a new law granted FDA authority to require studies be underway before accelerated approval, review divisions have, in some cases, given sponsors years of advance notice on expectations around study timing, according to a Pink Sheet review of NME accelerated approvals.
Top 5 Deals Of 2022: The Economic Drag On M&A Continues
Many of the same factors that held down large M&A transactions in 2021 carried over to 2022, which saw eight buyouts valued at $2bn+, headlined by Amgen’s $27.8bn purchase of Horizon.
Dong-A ST Achieves Therapeutic Equivalence With Stelara Biosimilar
Dong-A has achieved therapeutic equivalence for its ustekinumab biosimilar candidate DMB-3115 in clinical studies and now plans to file for marketing authorization for the product in both the EU and US.
Company Information
- Industry
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- IBC Pharmaceuticals, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice